HD-OPM Archive
Topics › Cancer

Daraxonrasib for pancreatic cancer already offered at Mass General Brigham

Louis Nervegna · Aug 18, 2026 · ♥ 9 reactions · 1 comments · original Facebook post
Cancer
AI summary & key facts

Louis reports that Mass General Brigham is treating pancreatic cancer patients with daraxonrasib through the FDA Expanded Access Program ahead of approval, and suggests other large hospitals may do the same. Coverage describes it as a historic pill that could double life expectancy in advanced disease.

MGH/Brigham hospital in Boston is already treating their pancreatic cancer patients with the new breakthrough drug daraxonrasib, even before the FDA has approved it.

They are doing this under the FDA's Expanded Access Program (EAP), often referred to as “compassionate use”.

I imagine other large hospitals are doing the same.

If you know someone with pancreatic cancer, this drug is already available. No one has to wait anymore.

Quoted:

Mass General Brigham Cancer Institute is excited to offer patients daraxonrasib, a groundbreaking new treatment for pancreatic cancer. Only weeks after this practice-changing therapy moved beyond clinical trials, our team began administering it through a carefully coordinated process designed to ensure safe access for patients. Mary Linton Peters, MD, a medical oncologist at Mass General Brigham Cancer Institute, discusses the significance of bringing this promising treatment to patients as quickly as possible. The Boston Globe chronicles Lazar Mandinov's journey as he took daraxonrasib for the first time. Patients receive ‘historic’ pill for deadly pancreatic cancer - The Boston Globe (BostonGlobe.com)

#daraxonrasibHD #pancreaticcancerHD #mghbrighamHD #cancerHD #rasHD

← newer: Group rule reminder: no politicsolder: Longevity clinic promotion for multi-system biological age t →